MethylScan is a low-cost blood test that detects cancers and organ diseases by analyzing DNA methylation, improving early diagnosis, and identifying disease origin.
Minimal residual disease (MRD) continues to be a central focus at the AACR meeting. The small numbers of cancer cells that ...
Detecting whether osteosarcoma, a rare but aggressive bone cancer that most often affects children and adolescents, has ...
A new light-based sensor can spot incredibly tiny amounts of cancer biomarkers in blood, raising the possibility of earlier and simpler cancer detection. The technology merges DNA nanotechnology, ...
PanCAN Chief Scientific & Medical Officer Dr. Anna Berkenblit takes a look at the latest in early detection blood tests ...
Scientists at Johns Hopkins University found that a blood test could detect cancer DNA more than three years before a patient receives a clinical diagnosis. The study, published in May in the journal ...
Performance evaluation of a reflex blood-based methylated ctDNA multi-cancer early detection test in individuals with obesity. A phase 1 study of intracerebroventricular (ICV) delivery of bivalent ...
Liquid biopsy encompasses a variety of molecular approaches to detect circulating tumor DNA (ctDNA) and has become a powerful tool in the diagnosis and treatment of solid tumors. Current applications ...
Some claim the new multi-cancer detection tests will “revolutionize” cancer screening. Others fear the “worried well” will succumb to slick marketing and subpar tests and overwhelm both primary care ...
Integrated DNA Technologies (IDT), a global leader in genomics, today issued the following statement about the recent landmark federal legislation that marks a significant step towards Medicare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results